J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Second Generation, WHO Country Cooperation Strategy, 2010–2015, Namibia
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
Technical Update
HIV Treatment
July 2017
Improving access to assistive technology for everyone, everywhere.
The first WHO Priority Assistive Products List was launched in May 2016. The List includes hearing aids, wheelchairs, communication aids, spectacles, artificial limbs, pill organizers, memory aids and other essential items for many... older people and people with disabilities to be able to live a healthy, productive and dignified life.
Available in English, Arabic, Chinese, French, Russian, Spanish
more
(2015)
Scoping question: Are antidepressants (specifically, tricyclic antidepressants and selective serotonin reuptake inhibitors) effective and safe in adolescents with moderate-severe depressive disorder for whom psychosocial interventions have proven ineffective?
Case Management; Guide for Tutors
Harm reduction: evidence, impacts and challenges
-10-
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover...nmental and civil society organizations to inform capacity-building, teaching and research agendas.
Web annex A provides the quantitative evidence reports, Web annex B summarizes the qualitative and economic evidence and Web annex C presents the Evidence-to-Decision frameworks.
more
Systematic Review Summary 4